Skip to main content

Table 2 Overview of levels of inflammatory-related and neurotrophic markers as well as inter-group comparisons for the cohorts IPD, PDLRRK2, and CON stratified by gender

From: Inflammatory profile in LRRK2-associated prodromal and clinical PD

 

Female

N = 211

Male

N = 208

Female

Male

Serum marker

IPD

N = 49

PDLRRK2

N = 73

CON

N = 89

IPD

N = 95

PDLRRK2

N = 69

CON

N = 44

p value

IPD

PDLRRK2

CON

p value

Post hoc

IPD

CON

p value

Post hoc

PDLRRK2

CON

p value

Post hoc

IPD

PDLRRK2

p value

IPD

PDLRRK2

CON

p value

Post hoc

IPD

CON

p value

Post hoc

PDLRRK2

CON

p value

Post hoc

IPD

PDLRRK2

Alpha fetoprotein

ng/ml

0.97

0.09–6.20

0.81

0.12–4.07

0.76

0.07–6.94

1.17

0.14–7.17

0.93

0.12–14.10

0.95

0.33–3.52

0.004

0.008

0.017

0.014

0.034

0.070

0.849

0.032

BDNF

(Brain-derived neurotrophic factor)

ng/ml

27.40

15.50–40.60

18.90

3.85–55.40

19.70

2.92–41.70

25.50

10.60–56.30

15.60

1.52–37.20

17.05

2.88–45.10

<0.001

<0.001

0.053

<0.001

<0.001

<0.001

0.311

<0.001

ENA-78

(Epithelial-derived neutrophil-activating peptide 78)

ng/ml

2.08

0.82–6.15

1.91

0.56–8.36

2.03

0.48–7.70

1.62

0.48–4.61

1.43

0.36–5.08

1.54

0.19–4.77

0.403

0.710

0.499

0.307

0.465

0.439

0.016

0.766

FABP

(Fatty-acid-binding protein)

ng/ml

4.97

2.24–81.10

3.71

0.40–26.70

2.87

0.97–12.00

5.91

1.45–22.20

4.44

1.37–18.90

4.04

1.44–11.50

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

0.006

0.002

GH

(Growth hormone)

ng/ml

1.39

0.11–14.40

2.47

0.08–26.50

1.61

0.11–29.60

0.79

0.04–14.90

0.87

0.08–30.80

0.36

0.07–24.50

0.145

0.326

0.415

0.117

0.004

0.083

0.005

0.030

ICAM-1

(Intercellular adhesion molecule 1)

ng/ml

152.62

65.70–224.00

161.00

73.50–262.00

160.00

80.00–288.00

149.00

71.60–273.00

150.00

51.60–246.00

150.50

83.40–232.00

0.340

0.544

0.722

0.018

0.251

0.183

0.529

0.267

IL-1-beta

pg/ml

2.18

1.02–4.97

1.83

0.29–4.53

1.84

0.56–4.10

2.57

1.11–17.10

2.38

0.71–5.22

2.17

1.02–3.30

0.052

0.018

0.726

0.239

0.012

0.019

0.179

0.033

IL-4

pg/ml

16.80

8.20–33.20

15.10

5.57–27.00

15.10

6.73–31.50

15.90

5.16–41.20

13.20

4.43–27.10

13.10

5.02–27.00

0.097

0.409

0.083

0.095

0.024

0.070

0.671

0.030

IL-6

pg/ml

4.36

1.67–20.30

4.26

1.27–16.30

3.65

1.27–99.10

5.29

1.67–13.90

5.63

2.00–13.70

4.71

2.17–9.57

0.008

0.017

0.053

0.020

0.033

0.346

0.002

0.254

IL-8

pg/ml

9.72

2.85–38.10

12.90

3.17–60.70

11.60

3.60–60.30

10.70

2.94–771.00

12.30

2.93–209.00

10.75

2.65–77.50

0.052

0.025

0.242

0.232

0.332

0.428

0.145

0.054

IL-10

pg/ml

4.68

1.72–36.10

3.72

1.78–19.20

3.26

1.78–21.80

5.09

2.55–36.90

3.29

1.78–13.80

3.26

1.78–7.59

0.001

<0.001

0.392

0.032

<0.001

<0.001

0.488

<0.001

IL-12-p40

ng/ml

0.29

0.12–0.71

0.21

0.10–0.49

0.24

0.07–0.69

0.25

0.07–0.88

0.22

0.07–0.62

0.16

0.07–0.36

0.007

0.004

0.228

0.016

<0.001

<0.001

0.015

0.059

IL-16

pg/ml

532.00

152.00–1000.00

543.00

237.00–1080.00

551.00

239.00–1370.00

522.00

224.00–1580.00

497.00

232.00–1310.00

520.00

268.00–760.00

0.537

0.265

0.535

0.663

0.611

0.851

0.603

0.403

IL-18

pg/ml

282.00

147.00–546.00

272.00

101.00–752.00

282.00

140.00–3360.00

304.00

137.00–925.00

312.00

133.00–771.00

306.00

141.00–681.00

0.521

0.390

0.725

0.362

0.094

0.812

0.040

0.020

Leptin

ng/ml

17.50

4.83–56.20

17.80

0.66–113.00

15.70

2.10–123.00

6.59

0.69–46.00

6.74

0.63–32.40

7.06

1.14–32.50

0.934

0.460

0.624

0.951

0.534

0.781

0.162

0.631

MCP-1

(Monocyte chemotactic protein 1)

pg/ml

396.00

177.00–941.00

366.00

152.00–1190.00

342.00

113.00–844.00

448.00

21.90–872.00

333.00

99.90–802.00

323.50

120.00–916.00

0.511

0.268

0.922

0.136

0.066

0.006

0.389

0.115

MDC

(Macrophage-derived chemokine)

pg/ml

425.00

292.00–676.00

516.00

125.00–964.00

474.00

93.80–1800.00

401.00

171.00–838.00

407.00

146.00–3860.00

483.00

188.00–950.00

0.113

0.289

0.286

0.014

0.014

0.017

0.381

0.036

MIP-1-beta

(Macrophage inflammatory protein-1-beta)

pg/ml

251.00

70.50–1160.00

217.00

18.40–588.00

215.00

62.20–955.00

237.00

29.70–737.00

207.00

75.90–1530.00

208.00

69.40–2520.00

0.034

0.011

0.097

0.264

0.762

0.536

0.491

0.189

MMP-3

(Matrix-metallo-proteinase-3)

ng/ml

14.80

4.42–37.10

13.50

6.31–120.00

12.30

6.08–92.90

23.00

7.28–59.90

24.00

8.01–48.40

23.55

9.61–53.80

0.013

0.052

0.029

0.057

0.594

0.891

0.703

0.283

MMP-9

(Matrix-metallo-proteinase-9)

ng/ml

16.80

6.80–28.00

20.90

9.28–46.20

19.60

12.60–61.60

21.20

12.10–42.30

27.00

15.60–121.00

25.40

16.10–37.80

<0.000

<0.001

0.100

<0.001

<0.001

0.222

0.058

<0.001

SCF

(Stem cell factor)

pg/ml

319.00

169.00–535.00

269.00

78.30–635.00

277.00

117.00–614.00

293.00

154.00–514.00

251.00

81.90–587.00

279.00

127.00–494.00

<0.001

<0.001

0.016

0.009

0.001

0.004

0.344

<0.001

TF

(Tissue factor)

ng/ml

0.28

0.08–0.72

0.25

0.12–0.67

0.24

0.07–0.53

0.43

0.08–23.80

0.32

0.13–0.74

0.30

0.15–0.43

0.064

0.231

0.002

0.833

0.011

0.057

0.187

0.102

TNF-alpha

(Tumor necrosis factor alpha)

pg/ml

58.70

11.70–110.00

60.00

21.20–129.00

60.00

27.60–110.00

76.50

39.20–187.00

73.30

30.30–143.00

69.30

49.80–105.00

0.666

0.294

0.925

0.427

0.200

0.299

0.161

0.296

TPO

(Thrombopoietin)

pg/ml

2.67

1.75–3.55

2.07

0.19–3.76

2.37

0.56–4.48

2.54

1.62–3.68

1.98

0.31–4.08

2.25

0.59–3.64

<0.001

0.002

0.042

0.001

<0.001

<0.001

0.069

<0.001

  1. Data are presented as median with range. p values reflect results from inter-group comparisons between IPD, PDLRRK2, and CON using multivariate variance analysis including age, regular intake of anti-inflammatory medication, and study site as co-variates. Correction for multiple testing for the number of groups that have been compared (n = 3 for IPD, PDLRRK2, CON = p < 0.016) was done according to Bonferroni and statistical significance was defined as p < 0.016. In case of significant differences between the three cohorts, we calculated pair-wise post hoc comparison including age, regular intake of anti-inflammatory medication, and study site as co-variates; and in the case of comparison between IPD and PDLRRK2, also disease duration was introduced as co-variate
  2. IPD patients with idiopathic Parkinson’s disease, PD LRRK2 patients with Parkinson’s disease carrying a LRRK2 mutation, CON healthy control individuals